Medication info

Empadown Duo Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Biconvex oval film-coated tablets that are white with a yellowish hue
Packaging
10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 60 tablets/bottle
Approval status
Active

MFDS item code 202201340 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Adult patients with type 2 diabetes who find it difficult to control blood sugar levels
  • patients with cardiovascular disease
View approved original text

This medication is suitable for adult patients with type 2 diabetes that are treated with a combination of empagliflozin and metformin. It helps improve blood sugar control when used as an adjunct therapy along with meal planning and exercise therapy. In cases where cardiovascular disease is present among patients with type 2 diabetes whose blood sugar is not adequately controlled, the impact of this medication on the occurrence of cardiovascular events should be referenced from expert guidelines. Overall, it is used to facilitate diabetes management by enhancing blood sugar control.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Precautions

This medication contains two components, empagliflozin and metformin hydrochloride, both of which lower blood sugar and are used for the treatment of type 2 diabetes. Care should be taken when taking this medication as it may lead to a serious condition known as lactic acidosis. Lactic acidosis is a condition where lactate builds up excessively in the body, which can be severe and potentially fatal. Additionally, using this medication with insulin or sulfonylureas can raise the risk of hypoglycemia, so blood sugar levels should be closely monitored. This medication is not administered to patients with severely impaired renal function or conditions such as acute infection, dehydration, severe heart failure, or acute myocardial infarction. Before and after tests using iodine contrast agents, this medication should be temporarily suspended due to the risk of worsening kidney function and lactic acidosis. Resuming the medication should occur after confirming that kidney function has returned to normal. It is contraindicated for women who are pregnant or may become pregnant, as well as for lactating women; patients with liver impairment should also avoid this medication. Regular kidney function tests should be conducted to verify safety during treatment, and especially elderly patients or those with slightly impaired kidney function should be tested more frequently. This medication may cause side effects such as gastrointestinal disturbances, hypoglycemia, urinary tract infections, genital infections, increased urination, decreased fluid volume, and should be reported to healthcare personnel if symptoms occur. Alcohol consumption may increase the risk of lactic acidosis, therefore it is important to avoid excessive drinking during treatment. Additionally, during treatment with this medication, irregular meals, intense exercise, and taking other medications may pose risks for hypoglycemia or ketoacidosis, so caution is advised. Notify a doctor immediately if pain, swelling, redness, etc., occurs in the genital or perineal area, as severe cases may require surgical treatment. In case of overdose, dialysis may be required, so the prescribed dosage must be strictly adhered to according to the physician’s instructions. Lastly, keep out of reach of children, and store in the original container to maintain quality.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 159 more
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvovaginitis
  • vulvar vaginitis
  • balanitis
  • perineal necrosis
  • vitamin B12 deficiency and depletion
  • decreased fluid volume
  • increased serum creatinine
  • decreased glomerular filtration rate
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • sensory loss
  • orthostatic dizziness
  • dizziness
  • drowsiness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urinary stones
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • gastric cancer
  • leiomyoma
  • pancreatic carcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent air or moisture from entering. It is advisable to store at room temperature, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Biconvex oval film-coated tablets that are white with a yellowish hue

Package unit

10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.